Paclitaxel + Carboplatin + Cisplatin + Veliparib + Pemetrexed
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-squamous Non-small Cell Lung Cancer
Conditions
Non-squamous Non-small Cell Lung Cancer
Trial Timeline
Sep 30, 2014 → Feb 21, 2020
NCT ID
NCT02264990About Paclitaxel + Carboplatin + Cisplatin + Veliparib + Pemetrexed
Paclitaxel + Carboplatin + Cisplatin + Veliparib + Pemetrexed is a phase 3 stage product being developed by AbbVie for Non-squamous Non-small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02264990. Target conditions include Non-squamous Non-small Cell Lung Cancer.
What happened to similar drugs?
3 of 20 similar drugs in Non-squamous Non-small Cell Lung Cancer were approved
Approved (3) Terminated (2) Active (15)
❌Camrelizumab;Pemetrexed and Carboplatin; Famitinib; + Camrelizumab;Pemetrexed and Carboplatin;PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02264990 | Phase 3 | Completed |
Competing Products
20 competing products in Non-squamous Non-small Cell Lung Cancer